Sofinnova Investments’s KALA BIO KALA Stock Holding History

Sofinnova Investments’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-295	Closed	-$6.48M	–	87
2020 Q1	$6.48M	Buy	+295	New	+$4.71M	0.6%	28

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sofinnova Investments's KALA Position: Q3 2020 in Review

Sofinnova Investments sold out of KALA BIO (KALA) in Q3 2020, closing a stake of 203 shares — an estimated $5.33M sold.

Sofinnova Investments first reported a position in KALA in Q1 2018 and held it in 10 quarters. The position peaked at $9.8M in Q1 2020. 105 funds tracked by Wall St. Rank hold KALA as of Q3 2020.

Sofinnova Investments reported no remaining KALA BIO position as of Q3 2020 after selling out during the quarter.
Sofinnova Investments sold 203 KALA BIO shares in Q3 2020, an estimated $5.33M.
Sofinnova Investments first reported a position in KALA BIO in Q1 2018 and held it in 10 quarters.
Sofinnova Investments's KALA BIO position peaked at $9.8M in Q1 2020.
105 funds tracked by Wall St. Rank held KALA BIO as of Q3 2020.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.